Skip to main content

Table 2 3-year and 5-year cost-effectiveness results by patient age at diagnosis

From: Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis

Time frame

 

Age group

RCHOP

CHOP

Incremental (95% CI)

ICER (95% CI) ($/LYG)

3 year

All ages

n = 1,099

n = 1,099

 

134,136 (71,368 - 398,400)

 

Mean costs

$76,815

$61,394

$15,421 (10,945 - 20,469)

 
 

Mean life-years

2 28

2 16

0 11 (0 06-0 19)

 

<60

n = 586

n = 586

 

73,037 (19,839 - 326,574)

 

Mean costs

$72,121

$61,860

$10,261 (3,680 - 16,464)

 
 

Mean life-years

2 51

2 37

0 14 (0 04-0 23)

 

60-79

n = 450

n = 450

 

302,881 (90,094 - dominated)

 

Mean costs

$82,149

$62,328

$19,822 (13,780 - 26,693)

 
 

Mean life-years

2 04

1 98

0 07 (−0 07 - 0 20)

 

≥80

n = 63

n = 63

 

128,766 (40,809 - dominated)

 

Mean costs

$80,456

$50,381

$30,075 (14,048 - 49,693)

 
 

Mean life-years

1 78

1 55

0 23 (−0 11 - 0 61)

 

5 year

All ages

n = 1,099

n = 1,099

 

61,984 (34,087 - 135,890)

 

Mean costs

$85,293

$68,995

$16,298 (10,829 - 22,044)

 
 

Mean life-years

3 44

3 18

0 26 (0 13 - 0 39)

 

<60

n = 586

n = 586

 

31,789 (6,195 - 160,587)

 

Mean costs

$77,453

$68,281

$9,172 (1,765 - 16,252)

 
 

Mean life-years

3 88

3 60

0 29 (0 09 - 0 47)

 

60-79

n = 450

n = 450

 

80,601 (34,420 - dominated)

 

Mean costs

$90,818

$72,006

$18,812 (12,124 - 26,301)

 
 

Mean life-years

3 02

2 79

0 23 (−0 02 - 0 45)

 

≥80

n = 63

n = 63

 

110,071 (33,478 - dominated)

 

Mean costs

$94,131

$54,114

$40,017 (18,077,68,826)

 
  

Mean life-years

2 46

2 10

0 36 (−0 22 - 0 98)

 
  1. CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; RCHOP, CHOP with rituximab; ICER, incremental cost-effectiveness ratio; CI, confidence interval.
  2. All values discounted (at r = 3%) and censored adjusted (with Inverse Probability Weighting). All costs are in 2009 Canadian dollars.